DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Corcept Therapeutics Incorporated

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

46 Comunicados de prensa

Ver todos los comunicados de prensa
29/07/2026
Web y redes sociales
Telefonía
Mercado de valores
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
22/07/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Farmacéutica
Salud
Oncología
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
17/06/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Oncología
Ciencia
Medicina - Varios
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
06/06/2026
Ciencia
Salud
Medicina - Varios
Biotecnología
Farmacéutica
Sanidad
Oncología
Eventos
Ferias y Congresos
Industria
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
29/05/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
27/05/2026
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
30/04/2026
Web y redes sociales
Telefonía
Mercado de valores
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
30/04/2026
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
23/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Ferias y Congresos
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0